Figure 2. Semaglutide^VT750 distribution in mouse brain.

(A) Acute and (B) steady-state brain distribution. Dots show individual measures of total fluorescence signal in selected brain regions with horizontal bar at group median. Asterisks indicate enriched regions with FDR of 5%; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. (C−F) Maximum intensity projection (MIP) of the average signal computed from individual brains (n = 4) overlaid onto the Common Coordinate Framework version 3 template from AIBS. (C) Representative vehicle signal from WT and Glp1r^–/– mice. (D) Acute semaglutide^VT750 signal, WT mice. (E) Steady-state semaglutide^VT750 signal, WT mice. (F) Acute semaglutide^VT750 signal, KO mice. (G) GLP-1R distribution visualized with whole-brain IHC. (H) Clustered heatmap of fluorescence signal in selected brain regions from mice treated with semaglutide^VT750, liraglutide^VT750, or vehicle (n = 4). Plot shows average semaglutide^VT750 versus liraglutide^VT750 signal per region. Regions selected based on at least 2.5-fold signal enrichment over vehicle-treated animals in either semaglutide- or liraglutide-treated groups. Hierarchical clustering of samples (columns) and brain regions (rows) based on Pearson’s correlation. AIBS, Allen Institute for Brain Science; DMH, dorsomedial hypothalamic nucleus; FDR, false discovery rate; lira, liraglutide; liraglutide^VT750, VivoTag750-S–labeled liraglutide; max., maximum; MEPO, median preoptic nucleus; min., minimum; MM, medial mammillary nucleus; PVH, paraventricular nucleus of the hypothalamus; PVp, posterior part; semaglutide^VT750, VivoTag750-S-labeled semaglutide; SO, supraoptic nucleus; TU, tuberal nucleus; Veh, vehicle.